Welcome to LookChem.com Sign In|Join Free

CAS

  • or

36017-64-8

Post Buying Request

36017-64-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

36017-64-8 Usage

Uses

A benzylisoquinoline alkaloid.

Check Digit Verification of cas no

The CAS Registry Mumber 36017-64-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,6,0,1 and 7 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 36017-64:
(7*3)+(6*6)+(5*0)+(4*1)+(3*7)+(2*6)+(1*4)=98
98 % 10 = 8
So 36017-64-8 is a valid CAS Registry Number.

36017-64-8Relevant articles and documents

Synergistic interaction of N-3-Br-benzyl-noscapine and docetaxel abrogates oncogenic potential of breast cancer cells

Dash, Shruti Gamya,Kantevari, Srinivas,Pandey, Swaroop Kumar,Naik, Pradeep Kumar

, p. 466 - 479 (2021)

Noscapine, an opium alkaloid, was discovered to bind tubulin, arrest dividing cells at mitosis, and selectively induce apoptosis to cancer cells. N-3-Br-Benzyl-Noscapine (Br-Bn-Nos), one of the derivatives of noscapine, was demonstrated to have improved anticancer potential compared with noscapine. We approached to evaluate the single and combined effect of Br-Bn-Nos and docetaxel (DOX) based on molecular modeling and cellular study. The individual predicted free energy of binding (?Gbind,pred) for Br-Bn-Nos and DOX with tubulin was found to be ?28.89 and ?36.07?kcal/mol based on molecular mechanics generalized Born solvation area (MM-GBSA) as well as ?26.21 and ?34.65?kcal/mol based on molecular mechanics Poisson Boltzmann solvation area (MM-PBSA), respectively. However, the ?Gbind,pred of Br-Bn-Nos was significantly reduced (?33.02 and ?30.24?kcal/mol using MM-GBSA and MM-PBSA) in the presence of DOX on its binding pocket. Parenthetically, the ?Gbind,pred of DOX was significantly reduced (?37.17 and ?32.80?kcal/mol using MM-GBSA and MM-PBSA) in the presence of Br-Bn-Nos on its binding pocket. The reduced ?Gbind,pred in the presence of Br-Bn-Nos and DOX together indicated a combination effect of both the ligands. The combined interaction of both the agents onto tubulin dimmer was also determined experimentally using purified tubulin, in which a?combination regimen of Br-Bn-Nos and DOX reduced the fluorescence intensity of tubulin to a higher value (68%) compared with the single regimen. Further, isobologram analysis revealed the synergistic effect of Br-Bn-Nos and DOX in antiproliferative activity using MCF-7 cell line at 48?hr (sum FIC?=?0.49) and at 72?hr (sum FIC?=?0.62). The combination dose regimen of Br-Bn-Nos and DOX blocks the cell cycle progression at the G2/M phase and induces apoptosis to cancer cells more effectively compared with the single regimen. Taken together, our study provides compelling evidence that the anticancer potential of noscapine derivatives may be substantially improved when it is used in a combined application with DOX for breast cancer.

A convenient synthesis of aryl-substituted N-carbamoyl/N-thiocarbamoyl narcotine and related compounds

Aggarwal, Shefali,Ghosh, Narendra N.,Aneja, Ritu,Joshi, Harish,Chandra, Ramesh

, p. 2458 - 2462 (2002)

The reaction of nornarcotine and 5-bromonornarcotine, synthesized from noscapine, with suitable aromatic isocyanates or isothiocyanates provides a general method for the synthesis of aryl-substituted N-carbamoyl or N-thiocarbamoylnarcotine and related compounds. Similarly, 15a has been prepared via the reduction of the lactone ring moiety of noscapine. Also, an improved procedure, which utilizes narcotine N-oxide · HCl for generation of nornarcotine, is described.

Discovery of noscapine derivatives as potential β-tubulin inhibitors

Bararjanian, Morteza,Bifulco, Giuseppe,Bruno, Ines,Hadian, Nasim,Lauro, Gianluigi,Mohebbi, Maryam,Nemati, Faezeh,Ruggiero, Dafne,Salehi, Peyman,Terracciano, Stefania

, (2020)

Twenty novel 1,2,3-triazole noscapine derivatives were synthesized starting from noscapine by consecutive N-demethylation, reduction of lactone ring, N-propargylation and Huisgen 1,3-dipolar cycloaddition reaction. In order to select the most promising molecules to subject to further biophysical and biological evaluation, a molecular docking analysis round was performed using noscapine as reference compound. The molecules featuring docking predicted binding affinity better than that of noscapine were then subjected to MTT assay against MCF7 cell line. The obtained results disclosed that all the selected triazole derivatives exhibited a remarkably lower cell viability compared to noscapine in the range of 20 μM in 48 h. In an attempt to correlate the biological activity with the ability to bind tubulin, the surface plasmon resonance (SPR) assay was employed. Compounds 8a, 8h, 9c, 9f and 9j were able to bind tubulin with affinity constant values in the nanomolar range and higher if compared to noscapine. Integrating computational predictions and experimental evaluation, two promising compounds (8h and 9c) were identified, whose relevant cytotoxicity was supposed to be correlated with tubulin binding affinity. These findings shed lights onto structural modifications of noscapine toward the identification of more potent cytotoxic agents targeting tubulin.

Identification of novel anti-cancer agents by the synthesis and cellular screening of a noscapine-based library

Nemati, Faezeh,Bischoff-Kont, Iris,Salehi, Peyman,Nejad-Ebrahimi, Samad,Mohebbi, Maryam,Bararjanian, Morteza,Hadian, Nasim,Hassanpour, Zahra,Jung, Yvonne,Schaerlaekens, Sofie,Lucena-Agell, Daniel,Oliva, María A.,Fürst, Robert,Nasiri, Hamid R.

, (2021/07/26)

Noscapine is a natural product first isolated from the opium poppy (Papaver somniferum L.) with anticancer properties. In this work, we report the synthesis and cellular screening of a noscapine-based library. A library of novel noscapine derivatives was synthesized with modifications in the isoquinoline and phthalide scaffolds. The so generated library, consisting of fifty-seven derivatives of the natural product noscapine, was tested against MDA-MB-231 breast cancer cells in a cellular proliferation assay (with a Z’ > 0.7). The screening resulted in the identification of two novel noscapine derivatives as inhibitors of MDA cell growth with IC50 values of 5 μM and 1.5 μM, respectively. Both hit molecules have a five-fold and seventeen-fold higher potency, compared with that of lead compound noscapine (IC50 26 μM). The identified active derivatives retain the tubulin-binding ability of noscapine. Further testing of both hit molecules, alongside the natural product against additional cancer cell lines (HepG2, HeLa and PC3 cells) confirmed our initial findings. Both molecules have improved anti-proliferative properties when compared to the initial natural product, noscapine.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 36017-64-8